James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K antagonist will present at the 2025 BIO CEO & Investor Conference taking place at The New York Marriott Marquis on February 10-11, 2025. Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics, Inc., will present an overview of the company and updates on the development of tecarfarin, a vitamin K antagonist (VKA) designed to be a better and safer anticoagulant than warfarin for individuals with implanted cardiac devices. The presentation will take place at 4:30 pm EST on Monday, February 10 in

Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. The fireside chat will take place at 10:30 a.m. Eastern time on Monday, January 13, 2025. T

Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit that featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3

PONTE VEDRA, Fla., Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Recent Highlights In early September, Cadrenal leadership met with the U.S. Food and Drug Ad

PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023, having an exercise price of $26.25 per share, at a reduced exercise price of $16.50 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective pos

PONTE VEDRA, Fla., Oct. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced that is has raised gross proceeds of approximately $5.1 million through its at-the-market (ATM) facility, selling an aggregate of 391,243 shares of common stock at a weighted average price of $13.15 per share. Fo

Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla., Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate Council of the Anticoagulation Forum (AC Forum). The AC Forum is the largest professional organization

PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, announced today it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024. Company Webcast Cadrenal's

SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees. Lisicki brings over 25 years of experience in the pharma/biotech sector, including as the Chief Commercial Officer of Arena Pharmaceuticals, where he provided global visionary leadership for the $6.7 billion growth-stage biopharmaceutical company through their acquisition by Pfizer in Mar

Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

S-8 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

SCHEDULE 13D - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

SCHEDULE 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

S-8 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

424B5 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

424B3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

EFFECT - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

S-3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

D - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)